Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.80down ₹0.10 (0.03%)BSE ₹352.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.
30 Oct: open ₹352.70, high ₹355.50, low ₹348.70
52-week range of traded prices to 30 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,333 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.75
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,63,63747.1% delivered
Biocon share news and announcements
1,771 announcements, routine notices left out, newest first. Page 35 of 36.
Jan 2009
9 Jan · Board meeting
Meeting on 21 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
16 Oct · Press Announcement
Press announcement dated October 16, 2008, titled "BIOCON's H1 FY'09 Sustains Growth In Challenging Conditions- Revenues Rs.734 crores (Including AxiCorp); Revenues Rs.593 crores (Excluding AxiCorp); EBITDA Rs.168 crores. PAT Rs.100 crores (Excluding MTM Loss of Rs.60 crores)". A copy of the press announcement along with Fact Sheet shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Oct · Results
Standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 46788 lacs for half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 6352 lacs for the half year ending on 30-SEP-2008.16 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 70323 lacs for half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 4006 lacs for the half year ending on 30-SEP-2008.16 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 24670 lacs for quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 3353 lacs for the quarter ending on 30-SEP-2008.16 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 43930 lacs for quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 2502 lacs for the quarter ending on 30-SEP-2008.10 Oct · Business
Press release dated October 09, 2008 titled "NeoBiocon and Abraxis Bioscience Launch Abraxane in the UAE For Treatment of Breast Cancer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
22 Sep · Business
Press release dated September 22, 2008 titled " Biocon is the 7th largest biotech employer in the world: Med Ad News ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Sep · Business
Press release dated September 08, 2008, titled "Biocon Limited presents human clinical data on IN-105 (oral insulin) at the EASD meeting in Rome". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
12 Aug · Corporate action
Members at the Annual General Meeting of the Company held on July 18, 2008 approved the issue of Bonus Shares in the ratio of one fully paid equity share for every equity share held in the Company. Further to the same, the Board has fixed September 12, 2008 as the record date for determining the eligibility and other conditions pursuant to the aforesaid approval by the members.
Jul 2008
18 Jul · Business
Press release dated July 18, 2008, titled "Biocon and Abraxis Bioscience Launch Abraxane in India For Treatment of Breast Cancer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jul · Meeting
Proceedings of the Annual General Meeting of the Company held on July 17, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jul · Business
Press release dated July 17, 2008, titled "Biocon is world's top 20 biotechnology company : Med Ad News". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jul · Press Announcement
Press announcement relating to the results dated July 17, 2008, titled "Biocon's Q1 Fy'09 impacted by Exceptional factors, Revenues Rs. 277 crores. EBITDA Rs. 70 crores, PAT Rs. 15 crores (MTM provision Rs. 26 crores)." The details of the press announcement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 26393 lacs for quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 1502 lacs for the quarter ending on 30-JUN-2008.17 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 22118 lacs for quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 3001 lacs for the quarter ending on 30-JUN-2008.7 Jul · News Verification
News Verification : The media had reports that Biocon Limited may hive off its research and development activity to a separate entity as part of its focus on innovation.. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Biocon Limited has vide its letter inter-alia stated, "We wish to inform that the company, with a view to achieve great focus on its research programmes is proposing to set up a new R&D entity for discovery and innovative drug development initiatives. The creation of the new entity is under way and further modalities are being worked out. Further the proposal of setting up a Greenfield formulations facility is part of the future expansion plans of the company. The company is yet to firm up its investment plans in terms of size and the time period for the said project."1 Jul · Board meeting
Meeting on 17 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Jun 2008
5 Jun · Meeting
Annual General Meeting of the Company will be held on July 17, 2008.4 Jun · Business
Press release dated June 04, 2008, titled "Biocon launches 'ERYPRO Safe(TM)'and 'NUFIL Safe (TM)' Pre-filled Syringes in collaboration with Safety Syringes Inc., USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
22 Apr · Corporate action
Register of Members and Share Transfer register shall remain closed for a period of 7 days from July 05, 2008 to July 12, 2008 (both days inclusive) for the payment of Dividend.22 Apr · Dividend
Board of Directors of the Company at its Meeting held on April 22, 2008 has recommended a dividend for the year (subject to the approval of the members at the ensuing Annual General Meeting) of Rs. 3/- per equity share (60%) and a special dividend of Rs. 2/- per share (40%).22 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 21975 lacs for quarter ending on 31-MAR-2008 against Rs. 23359 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 6203 lacs for the quarter ending on 31-MAR-2008 against Rs. 4729 lacs for the quarter ending on 31-MAR-2007.22 Apr · Press Announcement
Press announcement relating to results dated April 22, 2008, titled "Biocon Group Delivers Healthy Performance for FY 2007-08; Board Recommends 1:1 Bonus Shares & 100% Dividend.". A copy of the press announcement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Apr · Results
Standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 87693 lacs for year ending on 31-MAR-2008 against Rs. 85098 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 43494 lacs for the year ending on 31-MAR-2008 against Rs. 15835 lacs for the year ending on 31-MAR-2007.22 Apr · Results
Consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 105378 lacs for year ending on 31-MAR-2008 against Rs. 98573 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 46391 lacs for the year ending on 31-MAR-2008 against Rs. 20026 lacs for the year ending on 31-MAR-2007.22 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 26663 lacs for quarter ending on 31-MAR-2008 against Rs. 27824 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 6530 lacs for the quarter ending on 31-MAR-2008 against Rs. 6070 lacs for the quarter ending on 31-MAR-2007.22 Apr · Corporate action
Board of Directors of the Company at its Meeting held on April 22, 2008 has recommended, subject to the approval of Members, issue of Bonus Shares in the ratio of 1:1.15 Apr · Legal
Clarification to the article that has appeared on the Cover Page of 'Mint' on April 14, 2008 with the headline 'Biocon to buy US firm for $400 mn', that: "Biocon Limited would like to clarify that this article is speculative and deny the Headline and the related information contained in the article. While it is true that the company had earlier indicated an intent to acquire marketing companies abroad, no acquisition target has been identified and the information contained in the article is unsubstantiated. There has been no comment form any Biocon spokesperson, as is clearly mentioned in the article: 'A Biocon spokesperson declined to comment as the firm is in the silent period ahead of the announcement of its quarterly results in keeping with the guidelines of stock market regulator Securities and Exchange Board of India (SEBI)'. All announcements by the company will be made as per SEBI guidelines, with prior intimation to the Stock Exchanges".4 Apr · Board meeting
Inter-alia,to approve and take on record the audited financial results of the Company for the year ended on March 31, 2008 and to consider recommendation of payment of dividend, if any, for the year 2007-2008.
Feb 2008
11 Feb · Business
Press release dated February 11, 2008, titled "Biocon acquires 70% stake in German Pharmaceutical company, AxiCorp : Biosimilars will be main focus.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
17 Jan · Management
Auditor's report in respect of the audited financial results for the quarter ended December 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Business
Press release dated January 17, 2008, titled "Biocon and IATRICa Partner to develop Novel Immunoconjugate Therapeutics against Cancer and Infectious Diseases.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Business
Press release dated January 17, 2008, titled "Biocon's 9 Months FY 08 Registers Growth in Revenues & Profits Post Enzymes Divestment; Revenues Rs. 811 crs: EBITDA Rs. 240 crs: PAT Rs. 160 crs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 19419 lacs for quarter ending on 31-DEC-2007 against Rs. 21408 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 28404 lacs for the quarter ending on 31-DEC-2007 against Rs. 4751 lacs for the quarter ending on 31-DEC-2006.17 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 23734 lacs for quarter ending on 31-DEC-2007 against Rs. 24648 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 29183 lacs for the quarter ending on 31-DEC-2007 against Rs. 5531 lacs for the quarter ending on 31-DEC-2006.7 Jan · Board meeting
Inter alia, to approve/ take on record the audited financial results of the Company for the quarter ending December 31, 2007.
Oct 2007
18 Oct · Management
Auditor's report in respect of the audited financial results for the quarter ended September 30, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Oct · Business
Press release dated October 18, 2007, titled "Biocon Limited and Abraxis Bioscience announce the Approval of "Abraxine" in India for the treatment of Breast Cancer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Oct · Business
Press release dated October 18 2007, titled "Biocon's H-1 FY'08 Delivers 27% Profit Growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 23559 lacs for quarter ending on 30-SEP-2007 against Rs. 21911 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 4401 lacs for the quarter ending on 30-SEP-2007 against Rs. 3597 lacs for the quarter ending on 30-SEP-2006.18 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 54982 lacs for half year ending on 30-SEP-2007 against Rs. 46101 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 10679 lacs for the half year ending on 30-SEP-2007 against Rs. 8425 lacs for the half year ending on 30-SEP-2006.18 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 27899 lacs for quarter ending on 30-SEP-2007 against Rs. 24900 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 5395 lacs for the quarter ending on 30-SEP-2007 against Rs. 4534 lacs for the quarter ending on 30-SEP-2006.8 Oct · Board meeting
Inter alia, to approve/ take on record the audited financial results of the Company for the quarter and half year ending September 30, 2007.1 Oct · Divestment
Pursuant to the approval received through postal ballot from the Members of the Company, the results of which were declared on September 3, 2007 for the divestment of Enzymes Business to M/s Novozymes South Asia Private Limited, Bangalore ('Novozymes'), the Company has on October 1, 2007 completed all activities relating to the aforesaid divestment and transferred the Enzymes business to Novozymes
Sep 2007
21 Sep · Business
Press release dated September 21, 2007, titled "Biocon Limited presents human clinical data on IN-105 (oral insulin) at the EASD meeting in Amsterdam". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Sep · Results
Declaration of the Results of voting conducted by Postal Ballot in terms of the Notice dated July 18, 2007. Pursuant to Section 192A of the Companies Act, 1956 read with the Companies (passing of the resolution by postal ballot) Rules, 2001, approval of the Members of the Company was sought by means of Postal Ballot vide Notice dated July 18, 2007, for the purpose of divestment of the Enzymes business of the Company (other than the business in the field of Human Healthcare related Enzymes). The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2007
9 Aug · Business
Press release dated August 09, 2007, titled "Biocon Limited and Abraxis Bioscience announces Licensing Agreement for the commercialization of Abraxane in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Aug · Management
Kiran Kumar G has been appointed as the Company Secretary and Compliance Officer of Biocon Limited with effect from August 1, 2007
Jul 2007
30 Jul · Meeting
As per Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the consent of the Shareholders is required to be obtained by means of Postal Ballot for the following resolution: Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956, for sale of Enzymes business. The Board of Directors has appointed Mr. K. Srinivasan, a Consulting Company Secretary, Bangalore, as Scrutinizer for conducting the Postal Ballot voting process in a fair and transparent manner. The duly completed postal ballot form should reach the Scrutinizer before the close of working hours on August 31, 2007. The results will be announced by the Chairman or any Director of the Company on September 03, 2007. A copy of the Notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.